Many of today’s most promising retinal therapies are designed to act directly within the retina, and they’re getting bigger. But biological barriers and established delivery routes weren’t built for this new generation of drugs.
Unlocking their potential will require simpler, safer sub-retinal delivery approaches that can scale beyond specialist surgery.
Watch this short video by David Cottenden from TTP’s Drug Delivery team to find out more.
About TTP's Drug Delivery team
TTP’s Drug Delivery experts specialise in designing and engineering advanced drug delivery systems and combination devices, solving complex formulation and delivery challenges, and engineering robust, scalable devices for diverse therapies and routes of administration.
Backed by a broader team of 350+ scientiss, engineers and human factors specialists, TTP enables reliable real-world performance and has contributed to more than 70 systems, spanning autoinjectors and inhalation devices through to microneedles, infusion pumps and advanced local-delivery platforms. Find out more.
